Supplier of Magic Truffles to the Legal, Recreational Adult Use Market in the Netherlands
Phase 2 of Building out their Production Facility in the Netherlands
Message: PharmaDrug Inc. Proposes a Strategic Mutual Investment with Red Light Holland Corp.
Toronto, Ontario--(Newsfile Corp. - July 15, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that it has entered into a share exchange agreement with Red Light Holland Corp. (CSE: TRIP) ("RLH"), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands.
The two companies recognize the complimentary nature of their respective business models in the Dutch psychedelic market and will seek to collaborate on strategic initiatives. RLH's strategy to be a premier grower of psychedelic truffles with microdose packaging fits well with Super Smart's vision of elevating the Smart Store experience by introducing new products and an educational approach. The two companies plan to develop and foster a new market segment that seeks to use psilocybin to either attempt to potentially treat medical conditions holistically or to increase cognitive performance. On a combined basis, the two companies believe they can better execute on educating the market and increasing the profile of psychedelics and psilocybin in The Netherlands at first followed by other markets as they open up. Chairman and CEO of PharmaDrug said, "I am extremely excited by this motion to cooperate and I look forward to working closely with Todd (CEO and Director of RLH) to find ways to disrupt and expand the market in psychedelics."
Under the terms of the agreement, the Company will issue 9,333,333 units to RLH (the "PharmaDrug Units") at a price of $0.075 per PharmaDrug Unit, and RLH will issue 4,242,424 units (the "RLH Units") to the Company. Each PharmaDrug Unit will consist of (i) one common share of PharmaDrug, (ii) 0.9 of a PharmaDrug common share purchase warrant, with each whole warrant entitling the holder thereof to acquire one common share of the Company at a price of $0.13 until 48 months after the issuance of the warrants, and (iii) 0.1 of a PharmaDrug common share purchase warrant, each whole warrant entitling the holder thereof to acquire one common share of PharmaDrug at a price of $0.08 until 48 months after the issuance of the warrants. In addition, RLH subscribed for $200,000 of units of the Company, at a price of $0.075 per unit, each unit consisting of (i) one common share of PharmaDrug, and (ii) one PharmaDrug common share purchase warrant, each warrant entitling the holder thereof to acquire one common share of PharmaDrug at a price of $0.08 until the date that is 48 months after the issuance of the warrants.
Each RLH Unit will consist of one common share in the capital of RLH (a "RLH Share") and one RLH Share purchase warrant (a "RLH Warrant"). Each RLH Warrant will entitle the holder to purchase one additional RLH Share at an exercise price of $0.26 at any time until the date that is 48 months following its issuance, subject to an accelerated expiry option. If, following the date that is four months and one day following the date hereof, the volume weighted average trading price of the RLH Shares on the Canadian Securities Exchange (the "CSE") for any 10 consecutive trading days equals or exceeds $0.50, RLH may, upon providing written notice to the holders of RLH Warrants, accelerate the expiry date of the RLH Warrants to the date that is 30 days following the date of such written notice.
The Company intends to use the proceeds of the $200,000 investment for working capital and general corporate purposes.
All securities of the Company issued pursuant to the above transaction are subject to a four-month hold period under applicable securities laws expiring four months and one day after the closing.
Closing of the transaction is anticipated to occur on or about July 16, 2020.
About PharmaDrug Inc.
PharmaDrug Inc. is building an international controlled substance and natural medicine company with a focus on Europe. The Company owns 80% of Pharmadrug GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU. The Company also owns 100% of Super Smart, an early-stage retail company focused on consolidating the fragmented Dutch smartshop market. Smartshops are retail establishments in The Netherlands that specialize in the sale of psychoactive substances including psychedelic truffles.
For further information, please contact:
Daniel Cohen, Chairman and CEO
Please login to post a reply